What is Limb Girdle Muscular Dystrophy Market?
Limb-girdle muscular dystrophy is a term used for a group of diseases that cause weakness and muscle wasting in the arms and legs. The muscles most affected are the ones closest to the body (proximal muscles), particularly the muscles of the shoulders, upper arms, pelvic area, and thighs. The severity, age of onset, and characteristics of limb-girdle muscular dystrophy vary between the many subtypes of the disease and may even be inconsistent within the same family. Signs and symptoms can appear first at any age and generally worsen over time, although in some cases they can remain mild. The common features of LGMDs are the weakness and atrophy of the limb-girdle muscles. However, the age at which symptoms appear, and the rate and severity of disease progression can vary. There are two main groups of LGMDs. These two groups, called LGMD1 and LGMD2, are classified according to their inheritance patterns: autosomal dominant and autosomal recessive. There are few studies that confirm the effectiveness of exercise in muscular dystrophy of the limb-girdle. However, studies have shown that exercise can actually cause permanent damage to muscles due to strong muscle contraction.
The market study is being classified by Type (LGMD1 and LGMD2), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.
Myonexus Therapeutics, Inc. (United States), aTyr Pharma, Inc. (United States) and Sarepta Therapeutics (United States) are some of the key players profiled in the study.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Limb Girdle Muscular Dystrophy market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Limb Girdle Muscular Dystrophy market by Type, Application and Region.
On the basis of geography, the market of Limb Girdle Muscular Dystrophy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising Disease Burden of Limb-Girdle Muscular Dystrophy
- Growing Incidences of Orthopedic Disorders
- Rising Geriatric Population and Unhealthy Lifestyle Habits
- Increasing Awareness Campaigns for LGMD
- Emerging Demand from Economies
- Higher Cost and Maintenance of Physiotherapy Machines
- Rapid Technological Advancements & Product Innovation
- Increasing Awareness among People and With the Government’s Urgency for the Treatment of the Disease
- Increasing Investments in Biopharmaceutical R&D to Release Novel Disease Therapies
- Growing Acceptance of Acupuncture and Yoga
Key Target AudienceProviders of Limb-Girdle Muscular Dystrophy, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase